Helix公司外用干扰素α-2b获批开展III期临床试验

2012-05-24 jewell 生物谷

德国卫生部下属的药品监管机构——联邦药物与医疗器械研究所（BfArM），近日批准了Helix生物制药公司研发的外用型干扰素α-2b的III期临床试验，此试验将在宫颈低度病变患者中进行。 Helix称为了顺利开展药物试验，公司需要战略合作伙伴、资金赞助及干扰素α-2b原料供应。这家致力于肿瘤预防及治疗候选药品研发的生物制药企业，至今仍未公布其III临床试验将于何时开始。（生物谷Bioon.co

德国卫生部下属的药品监管机构——联邦药物与医疗器械研究所（BfArM），近日批准了Helix生物制药公司研发的外用型干扰素α-2b的III期临床试验，此试验将在宫颈低度病变患者中进行。

Helix称为了顺利开展药物试验，公司需要战略合作伙伴、资金赞助及干扰素α-2b原料供应。

这家致力于肿瘤预防及治疗候选药品研发的生物制药企业，至今仍未公布其III临床试验将于何时开始。（生物谷Bioon.com）

编译自German regulatory authority approves Helix trial of topical Interferon Alpha-2b

>>相关阅读

Helix 完成外用型Alpha-2B干挠素的第二期临床测试

政府降价令力促国内干扰素“平民化”

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1931401, encodeId=bb301931401a8, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sat Jan 12 01:37:00 CST 2013, time=2013-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088657, encodeId=1242208865e23, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Nov 20 03:37:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915761, encodeId=72181915e617a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Jan 05 05:37:00 CST 2013, time=2013-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652685, encodeId=1bdb165268590, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Oct 01 23:37:00 CST 2012, time=2012-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524530, encodeId=6527152453066, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587989, encodeId=4249158e989a4, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594318, encodeId=5bfd1594318a8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
2013-01-12 kksonne

#II期临床试验#

72 0
[GetPortalCommentsPageByObjectIdResponse(id=1931401, encodeId=bb301931401a8, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sat Jan 12 01:37:00 CST 2013, time=2013-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088657, encodeId=1242208865e23, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Nov 20 03:37:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915761, encodeId=72181915e617a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Jan 05 05:37:00 CST 2013, time=2013-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652685, encodeId=1bdb165268590, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Oct 01 23:37:00 CST 2012, time=2012-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524530, encodeId=6527152453066, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587989, encodeId=4249158e989a4, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594318, encodeId=5bfd1594318a8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
2012-11-20 839640778

#I期临床试验#

64 0
[GetPortalCommentsPageByObjectIdResponse(id=1931401, encodeId=bb301931401a8, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sat Jan 12 01:37:00 CST 2013, time=2013-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088657, encodeId=1242208865e23, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Nov 20 03:37:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915761, encodeId=72181915e617a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Jan 05 05:37:00 CST 2013, time=2013-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652685, encodeId=1bdb165268590, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Oct 01 23:37:00 CST 2012, time=2012-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524530, encodeId=6527152453066, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587989, encodeId=4249158e989a4, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594318, encodeId=5bfd1594318a8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
2013-01-05 juliusluan78

#III#

77 0
[GetPortalCommentsPageByObjectIdResponse(id=1931401, encodeId=bb301931401a8, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sat Jan 12 01:37:00 CST 2013, time=2013-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088657, encodeId=1242208865e23, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Nov 20 03:37:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915761, encodeId=72181915e617a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Jan 05 05:37:00 CST 2013, time=2013-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652685, encodeId=1bdb165268590, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Oct 01 23:37:00 CST 2012, time=2012-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524530, encodeId=6527152453066, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587989, encodeId=4249158e989a4, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594318, encodeId=5bfd1594318a8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
2012-10-01 医生2402

#I期临床#

66 0
[GetPortalCommentsPageByObjectIdResponse(id=1931401, encodeId=bb301931401a8, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sat Jan 12 01:37:00 CST 2013, time=2013-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088657, encodeId=1242208865e23, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Nov 20 03:37:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915761, encodeId=72181915e617a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Jan 05 05:37:00 CST 2013, time=2013-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652685, encodeId=1bdb165268590, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Oct 01 23:37:00 CST 2012, time=2012-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524530, encodeId=6527152453066, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587989, encodeId=4249158e989a4, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594318, encodeId=5bfd1594318a8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
2012-05-26 guihongzh

#II期临床#

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1931401, encodeId=bb301931401a8, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sat Jan 12 01:37:00 CST 2013, time=2013-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088657, encodeId=1242208865e23, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Nov 20 03:37:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915761, encodeId=72181915e617a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Jan 05 05:37:00 CST 2013, time=2013-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652685, encodeId=1bdb165268590, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Oct 01 23:37:00 CST 2012, time=2012-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524530, encodeId=6527152453066, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587989, encodeId=4249158e989a4, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594318, encodeId=5bfd1594318a8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
2012-05-26 guihongzh

#III期临床试验#

48 0
[GetPortalCommentsPageByObjectIdResponse(id=1931401, encodeId=bb301931401a8, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sat Jan 12 01:37:00 CST 2013, time=2013-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088657, encodeId=1242208865e23, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Nov 20 03:37:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915761, encodeId=72181915e617a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Jan 05 05:37:00 CST 2013, time=2013-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652685, encodeId=1bdb165268590, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Oct 01 23:37:00 CST 2012, time=2012-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524530, encodeId=6527152453066, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587989, encodeId=4249158e989a4, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594318, encodeId=5bfd1594318a8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat May 26 07:37:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
2012-05-26 智智灵药

#III期#

48 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

药械

Helix公司外用干扰素α-2b获批开展III期临床试验

相关资讯

科室

工具

服务